✦ LIBER ✦

Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia

✍ Scribed by Ruben A. Mesa; Alfonso Quintás-Cardama; Srdan Verstovsek

Book ID: 107540159
Publisher: Current Science Inc.
Year: 2007
Tongue: English
Weight: 188 KB
Volume: 2
Category: Article
ISSN: 1558-8211
DOI: 10.1007/s11899-007-0004-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thalidomide therapy for myelofibrosis wi

Thalidomide therapy for myelofibrosis with myeloid metaplasia

✍ Deborah A. Thomas; Francis J. Giles; Maher Albitar; Jorge E. Cortes; Srdan Verst 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 299 KB

Spleen neoangiogenesis in patients with

Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia

✍ Giovanni Barosi; Rosti Vittorio; Massa Margherita; Viarengo G. Luca; Pecci Aless 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

Dysregulation and overexpression of HMGA

Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia

✍ Joris Andrieux; Jean-Loup Demory; Brigitte Dupriez; Sabine Quief; Isabelle Plant 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

Among cytogenetic studies of patients affected with myelofibrosis with myeloid metaplasia (MMM), a rare chronic myeloproliferative disorder, we found several reports of structural abnormalities of the long arm of chromosome 12. Two MMM patients had a balanced translocation involving 12q: t(4;12)(q32

Increased granulocytic, erythrocytic, an

Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia

✍ Dr G. Chikkappa; A. L. Carsten; A. D. Chanana; P. Chandra; E. P. Cronkite 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

Leukemogenic risk of hydroxyurea therapy

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

Prognostic diversity among cytogenetic a

Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia

✍ Ayalew Tefferi; David Dingli; Chin-Yang Li; Gordon W. Dewald 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Abstract ## BACKGROUND Approximately 30–50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely defined by previous retrospective studies. The current prospective study addresses thi